These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26043217)

  • 21. Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review.
    Sawas A; Radeski D; O'Connor OA
    Ther Adv Hematol; 2015 Aug; 6(4):202-8. PubMed ID: 26288714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia.
    Poh C; Arora M; Ghuman S; Tuscano J
    Acta Haematol; 2021; 144(1):95-99. PubMed ID: 32348994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.
    Puvvada SD; Li H; Rimsza LM; Bernstein SH; Fisher RI; LeBlanc M; Schmelz M; Glinsmann-Gibson B; Miller TP; Maddox AM; Friedberg JW; Smith SM; Persky DO
    Leuk Lymphoma; 2016 Oct; 57(10):2359-69. PubMed ID: 26758422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticancer clinical efficiency and stochastic mechanisms of belinostat.
    El Omari N; Bakrim S; Khalid A; Albratty M; Abdalla AN; Lee LH; Goh KW; Ming LC; Bouyahya A
    Biomed Pharmacother; 2023 Sep; 165():115212. PubMed ID: 37541175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beleodaq approved for rare lymphomas.
    Cancer Discov; 2014 Sep; 4(9):978. PubMed ID: 25185167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.
    Sawas A; Ma H; Shustov A; Hsu P; Bhat G; Acosta M; Horwitz S; O'Connor OA
    Leuk Lymphoma; 2020 Aug; 61(8):2003-2007. PubMed ID: 32336176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenomics and histone deacetylase inhibitors.
    Goey AK; Sissung TM; Peer CJ; Figg WD
    Pharmacogenomics; 2016 Nov; 17(16):1807-1815. PubMed ID: 27767376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Belinostat approved for use in treating rare lymphoma.
    Thompson CA
    Am J Health Syst Pharm; 2014 Aug; 71(16):1328. PubMed ID: 25074945
    [No Abstract]   [Full Text] [Related]  

  • 30. New perspectives in the therapeutic approach of peripheral T-cell lymphoma.
    Gisselbrecht C; Sibon D
    Curr Opin Oncol; 2018 Sep; 30(5):285-291. PubMed ID: 30096094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor.
    Gimsing P
    Expert Opin Investig Drugs; 2009 Apr; 18(4):501-8. PubMed ID: 19335278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors: a review on class-I specific inhibition.
    Behera J; Jayaprakash V; Sinha BN
    Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies.
    Calvo E; Reddy G; Boni V; García-Cañamaque L; Song T; Tjornelund J; Choi MR; Allen LF
    Invest New Drugs; 2016 Apr; 34(2):193-201. PubMed ID: 26769244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
    Giaccone G; Rajan A; Berman A; Kelly RJ; Szabo E; Lopez-Chavez A; Trepel J; Lee MJ; Cao L; Espinoza-Delgado I; Spittler J; Loehrer PJ
    J Clin Oncol; 2011 May; 29(15):2052-9. PubMed ID: 21502553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
    Suresh PS; Devaraj VC; Srinivas NR; Mullangi R
    Biomed Chromatogr; 2017 Jan; 31(1):. PubMed ID: 27511598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
    Foss F; Pro B; Miles Prince H; Sokol L; Caballero D; Horwitz S; Coiffier B
    Cancer Med; 2017 Jan; 6(1):36-44. PubMed ID: 27981793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New drug therapies in peripheral T-cell lymphoma.
    Howman RA; Prince HM
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).
    Lu G; Jin S; Lin S; Gong Y; Zhang L; Yang J; Mou W; Du J
    Clin Epigenetics; 2023 Aug; 15(1):124. PubMed ID: 37533111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of histone deacetylase inhibitors in peripheral T-cell lymphoma: a systematic review and meta-analysis on prospective clinical trials.
    Yang P; Tao Y; Zhao A; Shen K; Li H; Wang J; Zhou H; Wang Z; Wang M; Qu Y; Zhang L; Zheng Y; Niu T
    Front Oncol; 2023; 13():1127112. PubMed ID: 37384289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
    d'Amore F; Radford J; Relander T; Jerkeman M; Tilly H; Osterborg A; Morschhauser F; Gramatzki M; Dreyling M; Bang B; Hagberg H
    Br J Haematol; 2010 Sep; 150(5):565-73. PubMed ID: 20629661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.